Search - tctmd.com

Displaying 21 - 40 of 61

Sort: Relevancy | Date

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Debate: Making the Case for Very Limited Use of Cangrelor!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Sorin J. Brener

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2016

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Presenter: Deepak L. Bhatt, Christian W. Hamm

October 30, 2016

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White, Philippe Généreux

October 15, 2015

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Gregg W. Stone

October 13, 2015

Presentation TCT 2015

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Freddy Abnousi

October 13, 2015

Presentation TCT 2015

Intravenous P2Y12 Inhibition: Role for Cangrelor

Presenter: George D. Dangas, Paul A. Gurbel, Robert A. Harrington

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Deepak L. Bhatt

October 12, 2015

Advertisement

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Switching to and From Cangrelor: When and How?

Why I Use Cangrelor for Primary PCI in STEMI!

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Debate: Making the Case for Very Limited Use of Cangrelor!

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

My Takeaways From TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Intravenous P2Y12 Inhibition: Role for Cangrelor

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content